#diabetescare
Eli Lilly becomes first health-care firm to briefly reach $1 trillion market value
Eli Lilly reached a historic milestone on Friday when it briefly surpassed a $1 trillion market capitalization, becoming the first health-care company in the world to enter a territory long dominated by technology giants. The company’s stock hovered near $1,048 per share during morning trading, touching the trillion-dollar threshold before pulling back slightly. It is only the second nontechnology business in the United States to reach this valuation, following Berkshire Hathaway’s climb
Eli Lilly becomes first health-care firm to briefly reach $1 trillion market value
Eli Lilly reached a historic milestone on Friday when it briefly surpassed a $1 trillion market capitalization, becoming the first health-care company in the world to enter a territory long dominated by technology giants. The company’s stock hovered near $1,048 per share during morning trading, touching the trillion-dollar threshold before pulling back slightly. It is only the second nontechnology business in the United States to reach this valuation, following Berkshire Hathaway’s climb
Novo Nordisk cuts Ozempic price to $499 for uninsured diabetes patients
Novo Nordisk has announced a major price cut for its popular diabetes medication Ozempic, offering the drug for just $499 per month for patients in the United States who are uninsured or paying out-of-pocket. This move represents a significant reduction from the previous list price of nearly $1,350, and it is aimed at improving access for patients who otherwise struggle to afford the medication. The drug will now be available at the lower price through the comp
Novo Nordisk cuts Ozempic price to $499 for uninsured diabetes patients
Novo Nordisk has announced a major price cut for its popular diabetes medication Ozempic, offering the drug for just $499 per month for patients in the United States who are uninsured or paying out-of-pocket. This move represents a significant reduction from the previous list price of nearly $1,350, and it is aimed at improving access for patients who otherwise struggle to afford the medication. The drug will now be available at the lower price through the comp









